Deal Ends Today·Save 35% annual plan
CNS Stimulant, Schedule IIReviewed for 2026 plan year

Does Aetna Cover Vyvanse?

The verdict

Covered on most plans

Aetna covers Vyvanse through CVS Caremark — generic lisdexamfetamine is the preferred formulary option, brand Vyvanse is non-preferred as generic supply improves. A Schedule II 70 mg/day quantity limit applies per CVS Caremark FEP CNS Stimulant Criteria (Policy 5.60.024, eff. April 1, 2026). Patients 22 and older require prior authorization; patients 21 and under are reviewed when the daily dose exceeds the FDA maximum. CVS Caremark allows pharmacist overrides and shortage-documented PAs for brand when generic is unavailable. Verify on the CVS Caremark or Aetna plan formulary.

MedicareCovered
CommercialCovered
See the difference

Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Aetna using your member ID.

Reviewed for 2026
Checked against the active plan year
Sourced from formularies
Aetna drug lists + CMS guidance
Updated as rules change
Coverage and prior-auth criteria shift often
Verify before you decide
Informational only — not insurance advice
Plan types

Medicare vs. commercial coverage

Whether Aetna covers Vyvanse depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.

Medicare

Part D & Advantage plans

Covered

Medicare Part D (Aetna/SilverScript): generic lisdexamfetamine is covered and generally preferred; brand Vyvanse may require prior authorization as generic supply stabilizes. The 70 mg/day Schedule II quantity limit applies. Verify the current tier on the Aetna/SilverScript Part D drug list, updated annually.

Commercial / Employer

Group & marketplace plans

Covered

Commercial/Employer: generic lisdexamfetamine preferred on the CVS Caremark standard commercial formulary; brand Vyvanse non-preferred. A 70 mg/day quantity limit applies per Policy 5.60.024. Age edit: patients 22 and older require PA for both diagnosis confirmation and quantity; patients 21 and under are reviewed when the daily dose exceeds the FDA maximum. ACA/Individual: generic preferred with QL; brand non-preferred. Medicaid (Aetna Better Health): generic covered per state PDL with PA and QL. During 2024, CVS Caremark plans temporarily added brand Vyvanse back due to generic supply constraints; those add-backs are being reversed. Pharmacist override or shortage-documented PA available when generic is unavailable.

Prior authorization

The 5 boxes you must tick to get approved

Commercial plans that will consider Vyvanse require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.

Requirements you meet0 / 5

Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.

What you'll pay

Your cost, three ways

What Vyvanse actually costs you swings enormously depending on how it's covered. Here's the realistic range.

No coverage

Paying cash

Brand Vyvanse: approx. $400–$558/month (Takeda list price, estimate). Generic lisdexamfetamine: approx. $200–$360/month cash, as low as approx. $60–$70 with a coupon.

List price with no coverage — before any manufacturer savings card.

PA approved

With coverage

Generic lisdexamfetamine at preferred tier: lowest cost-share (plan-specific copay or coinsurance — verify on CVS Caremark/Aetna formulary). Brand Vyvanse at non-preferred tier: higher cost-share. Medicaid (Aetna Better Health): nominal ($0–$4 typical). Cost-share varies by plan tier and deductible phase.

Typical monthly copay once prior authorization is approved.

All cost figures are estimates. Actual cost-share depends on your specific Aetna plan tier, deductible phase, and benefit design. Verify current copays on the CVS Caremark or Aetna plan formulary, or by calling Aetna member services.

Do it yourself

Check YOUR exact coverage in 3 steps

General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.

  1. 1

    Search the CVS Caremark or Aetna formulary online

    Go to aetna.com or caremark.com and use the drug lookup tool with your Aetna plan ID. Search 'lisdexamfetamine' (generic) and 'Vyvanse' (brand) to see the current tier, quantity limit, and PA requirements for 2026. The CVS Caremark standard commercial template places generic at the preferred tier.

  2. 2

    Call Aetna member services

    Call the number on the back of your Aetna card and ask: (1) Is generic lisdexamfetamine covered at a preferred tier on my plan? (2) Is brand Vyvanse non-preferred, and does it require a formulary exception? (3) What is the quantity limit (70 mg/day) and does the age-22 PA apply to me? (4) What is the brand override process if the generic is out of stock?

  3. 3

    Have your prescriber submit the prior authorization

    Your prescriber submits PA documentation to CVS Caremark including the ADHD or binge-eating disorder diagnosis, dose within the 70 mg/day QL, and — for patients 22 and older — confirms the diagnosis requirement per Policy 5.60.024. For brand Vyvanse, also document generic unavailability. CVS Caremark's PA portal routes the submission electronically from your prescriber.

If it's denied

Options if Aetna won't cover Vyvanse

A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.

Generic lisdexamfetamine

The preferred formulary option on the CVS Caremark standard commercial template. Same active ingredient as brand Vyvanse; FDA-approved August 2023. Cash approx. $200–$360/month; as low as approx. $60–$70 with coupon. Verify pharmacy stock — intermittent shortage continues.

Generic amphetamine/dextroamphetamine (Adderall generic)

Tier 1 on the CVS Caremark standard commercial formulary (most cost-effective stimulant option). Different chemical from lisdexamfetamine; not FDA-approved for binge-eating disorder. Cash approx. $17–$55/30 days. Prescriber must assess clinical appropriateness.

Generic extended-release amphetamine formulations

Various generic XR amphetamine products are typically low-tier on CVS Caremark commercial formularies. Verify specific product tier on the Aetna/CVS Caremark formulary.

These options are listed for information only — your own clinician decides what is appropriate for you.

Frequently Asked Questions

Aetna, through CVS Caremark, now prefers generic lisdexamfetamine over brand Vyvanse on its standard commercial formulary. Brand Vyvanse is non-preferred — it requires a formulary exception or shortage-documented PA. During 2024, CVS Caremark plans temporarily added brand Vyvanse back due to generic supply constraints; those add-backs are being reversed as supply improves. If your pharmacy cannot fill generic, ask your prescriber to document the shortage and request brand authorization through CVS Caremark.

CVS Caremark FEP CNS Stimulant Criteria, Policy 5.60.024 (effective April 1, 2026), sets the Schedule II quantity limit for lisdexamfetamine at 70 mg per day and establishes the age-based PA edit: patients 22 and older require prior authorization for both ADHD diagnosis confirmation and quantity; patients 21 and under are reviewed when the daily dose exceeds the FDA maximum. This policy applies to the Federal Employee Program and serves as the documented template for CVS Caremark standard commercial plans.

Most Aetna/CVS Caremark plans cover lisdexamfetamine for adult binge-eating disorder, consistent with FDA labeling. Prior authorization requires documentation of the BED diagnosis. Coverage on Aetna Better Health Medicaid plans depends on the state PDL. Binge-eating disorder is a Vyvanse-specific indication not shared by other amphetamine stimulants. Verify the BED PA criteria on the CVS Caremark formulary or with Aetna member services.

Per CVS Caremark Policy 5.60.024, patients 22 and older require prior authorization for lisdexamfetamine — both to confirm the ADHD or BED diagnosis and to approve the prescribed quantity within the 70 mg/day limit. Patients 21 and under are reviewed only when the prescribed daily dose exceeds the FDA-labeled maximum. Your prescriber submits the PA documentation electronically via the CVS Caremark portal. Approval is typically based on diagnosis confirmation and dose appropriateness.

All three carriers prefer generic lisdexamfetamine over brand Vyvanse, but the PBM differs: Aetna uses CVS Caremark, Cigna uses Express Scripts, and UHC uses OptumRx. Aetna through CVS Caremark has the most explicitly documented QL and age-edit numbers (Policy 5.60.024: 70 mg/day, age-22 PA). The generic-preferred outcome and Schedule II controls are consistent across all three. Verify your specific Aetna plan for exact tier and PA requirements.

This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Aetna before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.